multi-omics

Ambitious Bio builds biological data infrastructure for AI. Its product is Corpus, a whole-body dataset for biological AI: tissue-level molecular profiles matched across organs within each donor and linked to clinical history, generated prospectively under a single protocol and licensed to teams training biological models. Founded in 2024 and based in Cambridge, Massachusetts.

dataset licensing for AI trainingdeep mass-spectrometry proteomics (Orbitrap Astral)prospective tissue collection under consistent protocols

Cellarity is a drug discovery company that aims to solve complex diseases with medicines designed to correct the dynamic cell state. Its integrated multi-omics and AI-powered discovery platform maps networks of cell and gene interactions to predict and design oral Cell State-Correcting therapeutics that regulate gene switch mechanisms to restore proper cell function. Cellarity was launched by Flagship Pioneering in 2019.

Artificial Intelligence and Machine Learningcomputational biologydrug discoverymedicinal chemistry

DataTecnica builds software tools and platforms optimized for clients, accelerating research across federal health, biotech and philanthropy. The company applies AI, data science (machine learning, statistics, bioinformatics, epidemiology), computer science, biology and medicine to advance healthcare, pairing AI-enhanced tooling with subject matter experts. Founded in early 2017 by Mike Nalls, PhD.

AI-assisted toolingBioinformaticsclinical data analyticscloud-based pipelinesdata harmonizationdistributed systemsEpidemiologyGenomicshigh-performance computinghuman computer interactionmachine learningsoftware developmentstatistics